Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Abstract Background Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal. We have reported that targeting glycogen synthase kinase-3 (GSK-3) may be a potent...
Main Authors: | Selvi Kunnimalaiyaan, Victoriana K. Schwartz, Iris Alao Jackson, T. Clark Gamblin, Muthusamy Kunnimalaiyaan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4474-7 |
Similar Items
-
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
by: Octavio Silva-García, et al.
Published: (2020-12-01) -
SIRT1 and AROS suppress doxorubicin-induced apoptosis via inhibition of GSK3β activity in neuroblastoma cells
by: Jeong Woo Kim, et al.
Published: (2020-01-01) -
Different expression of GSK3β and pS9GSK3β depending on phenotype of cervical cancer: possible association of GSK3β with squamous cell carcinoma and pS9GSK3β with adenocarcinoma
by: Kwanghee Ahn, et al.
Published: (2019-05-01) -
Regulation of Autophagy by the Glycogen Synthase Kinase-3 (GSK-3) Signaling Pathway
by: Hsuan-Yeh Pan, et al.
Published: (2022-02-01) -
GSK-3β Contributes to Parkinsonian Dopaminergic Neuron Death: Evidence From Conditional Knockout Mice and Tideglusib
by: Junyu Li, et al.
Published: (2020-06-01)